Biotechnology drugs create new maze of concerns for hospitals.
Genetically engineered human insulin received federal approval nearly 10 years ago, but the pace of federal approval for new biotechnology drugs remains painstakingly slow. In any case, hospitals will soon face a multitude of financial, ethical and procedural issues surrounding these drugs.
K
K
Lumsdon
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001709:Biotechnology / Q000191:economics*; D016527:Drug Costs / Q000639:trends*; D004341:Drug Evaluation; D004345:Drug Industry / Q000191:economics; D004991:Ethics, Institutional; D006801:Humans; D010607:Pharmacy Service, Hospital / Q000191:economics*; D018805:Sepsis / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C068069:nebacumab